Interleukin-35 as an Emerging Player in Tumor Microenvironment

Wenhua Xue1,2*, Dan Yan1,2*, Quancheng Kan1,2**

1. Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
2. Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, China

*These authors contributed equally to this work.
**Corresponding author: Quancheng Kan, Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, No.1 Jianshe East Road, Zhengzhou, Henan, PR China, E-mail: kanqc@zzu.edu.cn, Tel: +86 071 66913047

© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2018.08.12; Accepted: 2019.03.05; Published: 2019.05.12

Abstract

IL-35 is the newest member of IL-12 family. A dimeric protein consisting of two separate subunits has manifested suppressive actions on immune system, which is counterproductive in the context of cancers. Various reports have confirmed its inhibitory role on immune system which is carried out via formation of IL-35-producing regulatory T cells (iTr35), increased Treg development and suppressive Th17 cells growth. Although last decade has seen a great deal of scientific interest on this subject, the exact role, precise signal transduction and elaborative functions of IL-35 in tumor microenvironment (TME) remained elusive. Search for anti-IL-35 therapies have exhibited limited success in animal models. Contrarily, few studies have denied the idea that IL-35 plays a role in cancer. The purpose of this review is to analyze the reported scientific data on continuous symphony of IL-35 in cancers since the inception of former.

Key words: IL-35, Cancer, Tumor microenvironment, Treg, Th17

Introduction

Interleukin 35 (IL-35) is a part of IL-12 family in addition to IL-12, IL-23 and IL-27. It is the newest member of IL-12 family which possesses anti-inflammatory and immunosuppressive properties [1]. It is released primarily from stimulated natural Treg cells [2], and its secretion is unconfirmed in human non-stimulated Treg cells [3]. IL35-producing regulatory B cell (i35-Breg) [4], stimulated pan T cells, CD4(+), CD8(+), CD4(+)CD25(-) T cell subpopulation [5] and CD8α+ DC [6] are described in literature as IL-35 producing cells. Besides, T cells [7] and B cells population [8], tumor-associated macrophages [9] and infiltrating dendritic cells [10] are also related with IL-35 upregulation. IL-35 is not a constitutive tissue product [11] and only expressed in certain tissues after pro-inflammatory activation by various stimuli such as tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), and IL-1β [12]. It was originally named in 13th International Congress of Immunology and currently grabs a significant attention of scientific community [13].

IL-35 is a dimeric protein consisting of p35 of IL12 and Epstein-Barr virus induced 3 (EBI3) subunits which are encoded by P35 and EBI3, respectively [1, 14-16]. The affinity of two subunits (p-35 and EBI3) to form a heterodimer was first explained by Devergne et al. in 1997 [17]. Interestingly, two subunits of IL-35 from human and mice can bind to each other, which explain its conservation between species [18].

Although IL-35 is mostly expressed in Treg cells but recent evidences have uncovered its much larger tissue distribution [11]. Various reports have indicated the presence of EBI3 and IL-12 p35, subunits of IL-35, in placental trophoblasts [19], Hodgkin lymphoma cells [10], acute myeloid leukemia cells [20], lung cancer cells [21] esophageal carcinoma, hepatocellular carcinoma, cervical carcinoma, and colorectal cancer [22, 23]. Similar studies have pointed
IL-35 as a major player in tumor microenvironment (TME) [24]. The presence of Foxp3+ Treg cells and Treg cells in TME is demonstrated as one of the sources of IL-35 production [25, 26].

Signal Transduction of IL-35

Unlike other members of IL-12 family of cytokines (IL-12, IL-23, and IL-27), IL-35 is not secreted by Antigen Presenting Cells (APCs) but its production has been reported primarily in Tregs [15, 27]. It is maintained that assembly of both α and β chains is necessary for the bioactive secretion of IL-35 [28]. Although signaling mechanism of IL-35 is not completely studied yet, Collison LW et al. has showed that IL-35 transmits signal through IL-35R, which is a “unique heterodimer of receptor chains IL-12Rβ2 and gp130 or homodimers of each respective chain” [14] (Figure 1). Although IL-35 is a subunit of IL-12 but its distinctive functions raised the suspicion about its unique signal transduction.

Recently, Collison LW et al. concluded that signal transduction of IL-35 does overlap with IL-12 and IL-27 transduction as it relays the signals using IL-12Rβ2 and gp130, which corresponds with IL-12 and IL-27 respectively [14]. Signal transduction is further carried through activation of pSTAT1 by gp130 chain and pSTAT4 by IL-12Rβ2 chain of receptor. Collison et al. explains that because the IL-35 signal transduction is carried out through two different but independent routes involving STAT signaling, the absence of either one of these two IL-35R chains will not affect the suppressive functions of IL-35 on T cells. However complete deletion of both chains of the receptor resulted in the loss of suppressive IL-35 effects [14]. Though conversion of conventional T cells into iTreg require the phosphorylation of both STAT1 and STAT4 from gp130 chain and IL-12Rβ2 chain respectively [29]. iTreg has specific tolerance promoting capabilities in parasitic infections and tumors. It is thought to work independently of (forkhead box P3) Foxp3, IL-10, and TGF-β [30]. Hetrodiamerization of STAT1 and STAT4 leads to upregulation of EBI3 or P35 which ultimately helps convert conventional T cells into iTreg. However a human study found that IL-35 can activate STAT1 and STAT3 heterodimers in human CD4+ T cells [31]. The expression pattern of IL-35R varies within the human system [3, 29, 32]. IL-12Rβ2 chain is expressed predominantly in activated T cells, natural killer cells [33] and dendritic cells [34]. IL-35 signaling in B cells is carried via IL-12Rb2: WSX-1, which activates phosphorylation of STAT1 and STAT3 [35].

IL-35 performs two distinctively notable functions. It suppresses the conventional T cells proliferation and transforms the conventional T cells into Treg cell population which are termed as iTreg as they act through IL-35 [36, 37]. It also suppresses immune responses via strengthening Treg development and inhibiting Th17 cells growth [38-40] (Figure 2).

Immunosuppressive effects of IL-35 have been linked with progression and amelioration of various diseases. However, the single most vital role that has grabbed attention of scientific community is implication of IL-35 in cancer milieu. The aim of this review is to summarize and analyze important published data on IL-35 effects on cancer progression and tumor microenvironment.

Evidences of IL-35 in cancer development

Immune cells consist of multiple checkpoints where distinct types of
immune cell(s) are responsible for any unwarranted entry. Like security blankets, immune system cells work in number of layers with each layer responsible for sustainability of respective microenvironment and destruction of unwanted endogenous and exogenous substances [41]. Hence functions of immune system cells is not restricted to killing the foreign substances brazenly, but also to evaluate the antigens, recognize and establish the self tolerance, maintain homeostatic conditions and even regulate the functions of other tissues. Such large scale intelligent modulation by immune system is largely exercised through its regulatory wings namely Tregs and Breg cells [42-45].

Immune evasion plays a key role in the development and progression of cancer [46, 47], which largely results from the failure of immune system to respond to particular tumor. This chiefly is achieved by the induction of immunosuppressive forces, which release cytokines to switch off the immune system and causes immune evasion of tumor. IL-35 is seen as critical immunosuppressive cytokine involved in immune evasion. The immune-cancer nexus is a well-established link as immune system plays a vital role in prevention, development and therapy of cancer [48]. Friedman and Liao explained that IL-35 is an important driver in cancer development as it enhances angiogenesis and blocks CD8+ T cells via releasing TGF-β [49]. One recent study has implicated IL-35 in breast cells cancer, showing greater induction of iTr35 in TME and causing inhibition of conventional T cell which subsequently converted in iTreg35 [50]. Similar evidence was provided by Wang et al. which not only consolidates the presence of IL-35 in TME but also emphasizes its remarkable role in tumorigenesis and related angiogenesis. According to the study the injection of J558-IL-35 cells (mouse plasmacytoma cells expressing IL-35) in BALB/c mice drastically increased the tumor size as compared to control. Moreover the protein lysates of IL-35 positive tumor contained higher concentration of IL-35, suggesting the definite part of IL-35 in tumor progression [51]. IL-35 neutralizing mAb was co-injected with J558-IL-35 cells in Rag2−/−BALB/c mice (mice that lack T and B lymohocytes), to know whether tumor progression was IL-35 specific. Intriguingly study found the abrogation of tumor growth in the presence of IL-35 neutralizing mAb compared to control. Study also emphasizes that IL-35 accumulates myeloid cells which in turn suppress the CTL responses in TME [51]. To understand and evaluate the effectiveness of anti-IL-35 therapy against cancer Liao et al. developed a series of in-silico experiments to find that continuous injection of drug provides better tumor control than intermittent supply of the same drug during the course of existing tumor [52]. A mathematical model was developed followed by in-silico experiments to evaluate the extent to which blocking IL-35 can reduce tumor growth. First, partial differential equations (PDEs) were used that entails interactions among different cells and cytokines. Situation arising in Wang et al. experiments [51] was assumed and two kinds of plasmacytoma cells were injected into wild type mice. One of the type consisted of tumor cells that were transfected with IL-35 to raise the amount of IL-35 into TME

Figure 2. Signal transduction and tumorigenic effects of IL-35. IL-35 receptor consists of gp130 and IL-12Rβ2 which upon activation phosphorylates STAT signaling. IL-35 suppresses the conventional T cells and promotes its conversion into iTreg35 which plays vital role in tumor immune evasion as they inhibit various immune responses owing to suppressive IL-35. Similarly pro-tumor activities are enhanced by the development of Treg cells and inhibition of Th17 responses.
while second used normal plasmacytoma cells that produced very small amount of IL-35. It was exhibited that model simulation corresponds with the experimental data shown in the experiments of Wang et al.

One of the more recent clinical evidence is put forward by Zhou et al. which showed that plasma level of IL-35 correlates with the progression and metastasis of prostate cancer and that it is independent predictor of the same [53]. An important study implicating IL-35 in prostate cancer is presented by Olson et al. in which authors presented a novel “population of CD8+CTLA-4+ IL-35-secreting tumor antigen-specific regulatory T cells” and it can affect the antigen-specific effectors responses via an IL-35 dependent mechanism [54]. Another authentication came from recent Wang K et al. study consisting of blood samples from 50 untreated gastric cancer patients, which showed significant upregulation of IL-35 producing B cells [55]. In the research of Pylayeva-Gupta’s group, they use a mouse model of pancreatic cancer demonstrated that IL-35+ Bregs are directly recruited to the tumor cell vicinity via a chemokine gradient of CXCL13 and promote tumorigenesis in IL-35 dependent manner [56, 57]. More recently it is pointed that the inhibitory cytokines like IL-35 and TGF-β play a significant role in immune escape of lung cancer cells. Same study confirmed the earlier reports that Foxp3 is an immune escape of lung cancer cells. Same study held low circulating IL-23: IL-35 ratio responsible for poor prognosis of breast cancer. Likewise Hamidinia and group implicated raised number of Treg cells and corresponding increase in IL-35 and other immune suppressor cytokines such as IL-10 and TGF-β in breast cancer patients with different clinical stages [68]. Study was performed on 40 breast cancer patient and complements the earlier reports. Similar tumor promoting results showing direct or indirect involvements of IL-35 in colorectal cancer are also reported [69]. In line with the previous data Yi Lu described IL-35 as an important biomarker in thyroid cancer diagnosis [70]. This data suggests the gross involvement of IL-35 in various types of cancers. Though exact mechanism of action through which IL-35 acts remains elusive, but there is abundant data implicating IL-35 in cancer.

**Induction of Neutrophils by IL-35 in cancer**

Neutrophils are an essential part of innate immune system [71, 72] and their participation in cancer development is increasingly realized [73, 74]. The duality of effects of neutrophils in cancer is implicated on its ability to get polarized by different cytokines to anti-tumor (N1) and pro-tumor (N2) phenotypes [75]. It is well established that pro-inflammatory cytokines (IL-6, TGF-β1, G-CSF) switch the neutrophils towards pro-tumor bias in TME [76-78]. Interestingly, it was described in a recent study that IL-35 activates pro-tumor (N2) bias in TME. An important study is put forward by Zou et al. which showing production of pro-inflammatory cytokines as result of IL-35 induction, shifting the neutrophils to TME. Interestingly study also presented the activation of macrophages in TME as result of IL-35, which secreted IL-1β and IL-6. STAT3 and ERK pathways in neutrophils were presented to be partly a cause for the suppression of T cells [79].

**IL-35 and Tregs in cancer**

Despite the growing evidence that directly implicates IL-35 for immune evasion of tumor cells due to its inhibitory actions, it is interesting to notice that majority of IL-35 is released from Treg cells. These Treg cells are recruited to tumor sites to avoid any miscalculation, the result of which is less number of CD4+ T cells and CD8+ CTLs in TME to combat
cancer. Intriguingly, depletion of Tregs cells exerted similar effects on cancer development as IL-35 when studied alone [80]. Correspondingly, inhibition of mere suppressive signaling from Treg cells devoid of depletion led to better treatment outcomes [81, 82]. Likewise, blockade of Treg cells steered the reversal of CD8+ T cells exhaustion [83]. Increased Treg cells population is also seen in breast cancer patients [66]. Hence it may be plausible to argue that the suppressive action of Treg on T cell growth corresponds with IL-35 actions on the latter. This obviously confirms Treg cells as major producers of IL-35 as manipulation of either of them led to identical findings. Therefore, targeting IL-35 for tumor suppression can also be a viable option. One of the verification is performed by Meghan et al. who introduced EBI3 monoclonal antibody (mAb) that neutralizes IL-35 specifically but does not affect Treg cells. Study findings manifested that neutralization of IL-35 resulted in improved tumor control in Wild-type C57BL/6 mice as compared to control mice [84]. An unorthodox study in this context is reported by Nicholl MB et al. which although described the role IL-35 in pancreatic cancers but found, rather surprisingly, that it was not expressed by Treg cells but expression found in epithelial derived pancreatic cancer (PCAN) cells [85]. In addition, cytokine-induced killer (CIK) cells are a heterogeneous cells population expressing cell markers for both T cells and natural killer cells and launch a robust attack against cancer cells [86]. CIK have well reported advantages in hematological malignancies and solid tumors in the past [87-89]. Studies also report the inverse relationship in number and function between Treg cells and CIK, understandably through release of inhibitory cytokines by former [90, 91]. Alternatively it is also documented that dendritic cells co-cultured with CIK led to suppression of Treg cells and its inhibitory cytokines [92-94]. Interestingly, Ying Pan and colleagues showed that Tregs cells and IL-35 concomitantly increased in a time-dependent manner during the generation of CIK cells as compared to DC-CIK co-culture, which notably suspended the expression of Treg cells and IL-35 [95].

Role of EBI3 in IL-35 pro-tumor effects

EBI3 can form IL-12p35 part of heterodimer to constitute IL-35 [96]. It could be interesting to notice what effect EBI3 knockout can exert on tumor promotion. Theoretically, EBI3 knockout would stall IL-35 production from Tregs which would result in raised CTL and improved tumor protection. Contrary to the theoretical perception Zhenzhen Liu and group [97] found increased tumor growth, decreased CD8+ T cells and higher CD4+FoxP3+ Treg cells in EBI3-defecient C57BL/6 and BALB/c mice as compared to control. This is due to the fact that EBI3 is responsible for secretion of both IL-27 and IL-35 which is a tumor suppressor and tumor promoter, respectively. Authors argued that IL-27 phenotype dominantly prevail in EBI3 deficient mice and IL-10 signaling play a vital role in the absence of IL-27 and IL-35 from Treg cells. Expectedly, depletion of Tregs led to positive tumor outcome. It possibly means the superior effectiveness of Tregs depletion in tumor control as compared to IL-35 alone. Esophageal cancer is one of the lethal types of cancer affecting approximately 450000 patients worldwide and ranked number six in cancer mortality rates [98]. It was discussed by Eric W. Lin et al. that IL-35 is a part of esophageal cancer TME as part of suppressive cytokine released directly from Treg cells to curtail the T cells population and hence playing a role in tumor evasion. Similar results were boasted in gastric ulcer where expression of EBI3 and p35 was higher and correlated with clinicopathological factors of gastric ulcer [99]. Another study manifested that IL-35 applies its anti-inflammatory effects through downregulating the expression of IL-17, IL-22 and Retinoic acid receptor-related orphan receptor gamma t (RORγt) by inducing the EBI3 subunit [100].

Interplay of IL-35 and TH17 in cancer

IL-35 signaling is also reported to cause the suppression of immune cells-led anti-tumor activities in TME thorough inhibiting the Th17 cells growth [50, 101]. The exact role of Th17 in cancer development remains a controversial subject itself due to Th17 cells plasticity. Both pro-inflammatory and anti-inflammatory effects of Th17 are put forward, but number of studies in relation to IL-35 is not enough to be conclusive. For example, one study manifests Th17 as pro-tumor attributed largely to the secretion of IL-17 [102, 103], while other exerts anti-tumor actions by promoting immune cells into tumors, activating effector CD8(+) T cells, or directly through converting toward Th1 phenotype and producing IFN-γ [104]. Although IL-35 inhibits the Th17 cells [38], but it is premature to jump to conclusion that it can also play a role in cancer immunity as Th17 cells inhibition can also lead to the suppression of its anti-tumor action via different mechanism described above. Therefore it may be plausible to say that IL-35 induced Th-17 inhibition inconclusively and/or partially suppresses the anti-tumor activities.

Functional Contradiction of IL-35

There are some contradictory results as well, pressing the point that IL-35 does not act in a same way in all types of cancer and hence its role can be
unique in different kind of immune situations. For example it was shown that IL-35 might have inhibitory actions in colon cancer growth. Not only was the expression of IL-35 in colon cancer low but the anti-tumor effects of IL-35 on colon cancer cell lines also appeared in a dose dependent manner [105]. It was found that mechanistically the inhibition of β-catenin is involved in the IL-35 induced blunting action on colon cancer. Authors indicated that the reason for these contradictory results are unclear and requires further investigation. Such paradoxical results are also endorsed by Jun Long et al. in one clinical study which revealed the data form 75 Hepatocellular carcinoma (HCC) patients. IL-35 expression in advance stages of HCC was lowered as compared to early stages of the disease. The expression of IL-35 changed inversely as the key feature of HCC e.g. tumor size, microvascular invasion, and histological grades advanced [106]. Conversely, Fu et al. highlighted that overexpression of IL-35 is correlated with the HCC aggressiveness [107]. Correspondingly, the effects of IL-35 in inhibiting cancer development, curtailing tumor growth and inducing the apoptosis in human cancer cells were reported by Long et al. in 2013 [23].

Although ongoing symphony of IL-35 effects on cancer is still in infancy and are not well understood yet few studies have pointed the possible targets against IL-35. For instance, a group of scientist has showed that IL-15 can help enhance cytotoxicity of CIK cells via suppressing Treg cells and IL-35 concomitantly [108]. Understanding IL-35 and its signal transduction can be helpful in the formulation of vaccines against various inflammatory ailments including particular kind of cancers [109].

IL-35 in other inflammatory states

Despite that IL-35 remains a culprit in cancer therapeutics yet it plays an important regulator role in many autoimmune diseases. IL-35 is expectedly credited as therapeutic option for autoimmune diseases and pro-inflammatory states due to its anti-inflammatory effects, suppression of T cells and proliferation of Treg cells. Beneficial effects of IL-35 are described in atherosclerosis [110, 111], allergic airways disease [112-114], and smoke-induced lung inflammation [115]. Likewise decreased level of IL-35 has been correlated with patients suffering from stable angina pectoris, unstable angina pectoris, and acute myocardial infarction [116]. Ectopic expression of IL-35 in pancreatic β cells prevents development of diabetes mellitus in NOD mice. Bettini et al. found that IL-35 expression protects animals from autoimmune diabetes via curbing T-cell infiltration and proliferation [117]. Similarly, intraperitoneal injection of rIL-35 has showed to decrease the incidence, intensity and progression of collagen-induced arthritis (CIA). Yuejun Liu et al. described that IL-35 can reduce acute graft-versus-host disease (aGVHD) by expanding Tregs and repressing Th1 responses [118]. EBI3-/- mice have confirmed the anti-inflammatory properties of IL-35 in various diseases. For instance, Corona virus-induced encephalomyelitis and experimental autoimmune encephalomyelitis (EAE) were worsened in EBI3-/- mice [119]. Controversial reports have been observed regarding IL-35 role in rheumatoid arthritis [120-123]. In addition, raised liver inflammation in induced liver fibrosis in IL-12p35-/- mice has been observed by Tsuda et al. [124]. The detailed review about possible role of IL-12 family including IL-35 in inflammation, autoimmune disease and infections can be read elsewhere [125, 126].

IL-35 as Drug Target

Although the research on IL-35 has not reached a conclusive stage, but it has been increasingly realized as a potential drug target. Until now, there are no significant efforts reported which target IL-35 for cancer therapies. The lack of scientific attention is partly due to shorter span since IL-35 has been put to light. Its pleitropic effects, multiple inducing molecules and more than one subunit with independent transductions can be other reasons why it has not been yet. While it’s relatively hard to target, the benefits to overcome it may be huge. Immune evasion has remained a hardest nut to crack in cancer therapies and targeting IL-35 can be possible way forward.

Conclusion

It is plausible to conclude that IL-35 is a key player in TME which plays its part in progression of various cancers. It acts via activating receptor consisting of two distinct subunits which lead to STAT1 and STAT3/4 phosphorylation to exert its suppressive actions on immune system. The inhibitions on immune system exerted by IL-35, primarily through forming iTregs and feedback upregulation of its own expression spur the onset of tumor immune evasion. Although various studies in last decade have implicated IL-35 in TME, its exact mechanism is still elusive. Furthermore there are some studies that contradict the generally accepted and well reported role of IL-35 in cancers. This review analyzed the array of studies on cancer since the inception of IL-35. It can be safely concluded that role of IL-35 in cancer is developing but still in infancy and requires further data to exactly locate its functions in TME. This review can be important not only for future
studies in this direction but may also help scientific community searching anti-IL-35 therapies to treat cancers.

Future outlook
IL-35 is relatively new to the spectrum of cytokines, which promise potentials to be a drug target. The research on IL-35 has not reached its peak and many dimensions are yet to be explored. Whether it’s completely an inhibitory cytokine in cancer biology? To what extent immune evasion is dependent on IL-35 and at what level? And can we block IL-35 to curtail its effects if answer to all above question is yes? These, among others, remain questions for scientific community needing to be answer.

Acknowledgments
This work was supported by the National Natural Science Foundation of China (grant number 31670895 to QK).

Author contributions
WX and DY collected the literature and wrote the manuscript. QK designed and reviewed the manuscript.

Competing Interests
The authors have declared that no competing interest exists.

References
1. Su LC, Liu XY, Huang AF, Xu WD. Emerging role of IL-35 in inflammatory autoimmune diseases. Autoimmun Rev. 2018; 17: 665-73.
2. Teymouri M, Pirro M, Faraolino F, Gargaro M, Sahebkar A. IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases. Int J Cancer. 2018; 143: 2105-15.
3. Bardel E, Larousserie F, Charlot-Rabiege P, Coulomb-L’Hermitte A, Devergne O. Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. J Immunol. 2008; 181: 6988-905.
4. Egwuagu CE, Yu CR, Sun L, Wang R. Interleukin-35: Critical regulator of immunity and lymphocyte-mediated diseases. Cytokine Growth Factor Rev. 2015; 26: 587-93.
5. Gutte K, Reinhold D. Stimulated human peripheral T cells produce high amounts of IL-35 protein in a proliferation-dependent manner. Cytokine. 2013; 64: 46-50.
6. Haller S, Duval A, Migliorini R, Stevanin M, Mack V, Acha-Orbea H. Interleukin-35-producing CD8α+ dendritic cells acquire a tolerogenic functional interleukin 12 receptor complex is composed of two ακ̂ receptor subunits. Proc Natl Acad Sci USA. 1996; 93: 14002-7.
7. Grohmann U, Belladonna ML, Bianchi R, Orabona C, Ayroldi E, Fioretti MC, et al. IL-12 acts directly on DC to promote nuclear localization of NF-κB molecule, throughout human pregnancy: involvement of syncytiotrophoblasts and extravillous trophoblasts. Am J Pathol. 2005; 166: 1217-28.
8. Haller S, Duval A, Migliorini R, Stevanin M, Mack V, Acha-Orbea H. Interleukin-35-producing CD8α+ dendritic cells acquire a tolerogenic
9. Li X, Mai J, Virtue A, Yin Y, Gong R, Sha X, et al. IL-35 is a novel responsive anti-inflammatory cytokine—a new system of categorizing anti-inflammatory cytokines. PLoS ONE. 2012; 7: e33628.
10. Bello RC, Chin VK, Abd Rahman Isnadi MF, Abd Majid R, Atmadini Abdullah M, Lee YT, et al. The role, involvement and function(s) of Interleukin-35 and Interleukin-39 in disease pathogenesis. Int J Mol Sci. 2018; 19.
40. Kochetkova I, Golden S, Holderness L, Callis G, Pascual DW. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol. 2010; 184: 7144-53.

41. Thompson AE. JAMA patient page. The immune system. JAMA. 2015; 313: 1686.

42. Payne KK. Lymphocyte-mediated immune regulation in health and disease: the Treg and gammadelta T cell co-conspiracy. Immunol Invest. 2016; 45: 767-75.

43. Ray A, Dittl BN. Mechanisms of regulatory B cell function in autoimmune and inflammatory diseases beyond IL-10. J Clin Med. 2017; 6:

44. Wang SS, Liu W, Ly D, Xu H, Qu L, Zhang H. Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. Cell Mol Immunol. 2019; 16: 6-18.

45. Najafi M, Farhood B, Mortezae K. Contribution of regulatory T cells to cancer: a review. J Cell Physiol. 2018;1-11

46. Mirlekar B, Michaud D, Searcy R, Greene K, Pylayeva-Gupta Y. IL35 hinders cytokines secretion by participating in TLR4 regulation of Foxp3 transcription and inflammatory diseases beyond IL-10. J Clin Med. 2017; 6: 72.

47. Rakic A, Beaudry P, Mahoney DJ. The complex interplay between neutrophils and Tregs. Cytomembr Cell Res Clin Oncol. 2011; 137: 305-10.

48. Delgoffe GM, Woo SR, Turnis ME, Gravono DM, Guy C, Overace AE. Stability and function of regulatory T cells is maintained by a paradox. Int J Biol Sci. 2012; 8: 228-35.

49. Nicholl MB, Ledgewood CL, Chen X, Bai Q, Qin C, Cook KM, et al. IL-35 promotes pancreatic cancer growth through enhancement of proliferation and inhibition of apoptosis: evidence for a role as an autocrine growth factor. Cytokine. 2014; 76: 126-33.

50. Coffelt SV, Buttgereit P. CD8+ regulatory T cells with potent antitumor cell activity. J Exp Med. 1991; 174: 139-49.

51. Thompson AE. JAMA patient page. The immune system. JAMA. 2015; 313: 701-15.

52. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Semin Cancer Biol. 2015; 35: Suppl: S185-98.

53. Mehlich D, Garbicz F, Włodarczyk PK. The emerging roles of the polyclonistic miR-196a expression in prostate cancer - a comprehensive review. Biomed Pharmacother. 2018; 107: 1183-95.

54. Olson BM, Jankowska-Gan E, Becker JT, Vignali DA, Burlingham WJ, McNeel DG. Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol. 2012; 189: 2415-23.

55. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of dendritic cells with potent antitumor cell activity. J Exp Med. 1991; 174: 139-49.

56. Sun YX, Kong HL, Liu CF, Yu S, Tian T, Ma DX, et al. The imbalanced profile mediated through binding of B7-H1-FR4 complex to IL2 and CD3 co-stimulator elements. J Leukoc Biol. 2018. 105: 251-262.

57. Li Y, Yang W, Wu B, Liu Y, Li D, Guo Y, et al. KDM3A promotes inhibitory T-cell function and responsiveness to immunotherapy in pancreatic cancer. Cancer Immunology Research. 2018; 6: 1014-24.

58. Li Y, Yang W, Wu B, Liu Y, Li D, Guo Y, et al. KDM3A promotes inhibitory T-cell function and responsiveness to immunotherapy in pancreatic cancer. Cancer Immunology Research. 2018; 6: 1014-24.

59. Sun YX, Kong HL, Liu CF, Yu S, Tian T, Ma DX, et al. The imbalanced profile and function of CD4+CD25+ cells in cytokine-induced killer cells. Zhonghua Yi Xue Za Zhi. 2005; 85: 3134-8.

60. Sun YX, Kong HL, Liu CF, Yu S, Tian T, Ma DX, et al. The imbalanced profile and function of CD4+CD25+ cells in cytokine-induced killer cells. Zhonghua Yi Xue Za Zhi. 2005; 85: 3134-8.

61. Huang C, Li N, Li Z, Wang J, Zhu A, Zhang W, Hua J, Jian P, Zhu T, et al. Tumor-derived IL-35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression. Nat Commun. 2017; 8: 14035.

62. Hori SC, Nomura T, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol. 2014; 27: 1-7.

63. Delgoffe GM, Woo SR, Turnis ME, Gravono DM, Guy C, Overace AE. Stability and function of regulatory T cells is maintained by a paradox. Int J Biol Sci. 2012; 8: 228-35.

64. Nicholl MB, Ledgewood CL, Chen X, Bai Q, Qin C, Cook KM, et al. IL-35 promotes pancreatic cancer growth through enhancement of proliferation and inhibition of apoptosis: evidence for a role as an autocrine growth factor. Cytokine. 2014; 76: 126-33.

65. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991; 174: 139-49.

66. Mesiano G, Todorovic M, Gamaitoni I, Leuci V, Gaudioe Diegol, L., Carnevali-Sfiania F, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther. 2012; 12: 673-84.

67. Olioso P, Giancola S, Contento A, Iacone A. Immunotherapy with cytokine-induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol. 2009; 27: 139-49.

68. Bhatia M, Delgoffe GM, Yip L, Liu J, Hsu D, Shu Y, et al. Interleukin-35 hinders endogenous antitumor T-cell immunity and responsiveness to immunotherapy in pancreatic cancer. Cancer Immunology Research. 2018; 6: 1014-24.
